Active Not Recruiting OBSERVATIONAL NCT04654208

Swedish Ibrance Registries Insights (SIRI) (SIRI)

Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)

Sponsor: Pfizer

Conditions Malignant Neoplasm of Breast

Interventions palbociclib

Updated 6 times since 2021 Last updated: Nov 22, 2025 Started: Dec 15, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04654208, this observational or N/A phase trial focuses on Malignant Neoplasm of Breast and remains ongoing. Sponsored by Pfizer, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting
Sep 2024 — Dec 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jan 2023 — Jul 2024 [monthly]

Recruiting
May 2021 — Jan 2023 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jan 2021 — May 2021 [monthly]

Not Yet Recruiting

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sollentuna, Sweden